Discussion

Limited understanding of drug mechanism-of-action and pharmacological resistance contributes to poor efficacy and attrition at later stages of drug discovery and development. We demonstrate how complex high content assays, intravital imaging and Reverse Phase Protein Microarray (RPPA) technologies can combine to enable a robust and unbiased approach to profiling compound mechanism-of-action and validating target hypothesis within disease relevant in vitro and in vivo settings.